<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sun Y</submitter><funding>National Natural Science Foundation of China</funding><pagination>E2218</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7248705</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(9)</volume><pubmed_abstract>Gemcitabine (dFdC) demonstrates significant effectiveness against solid tumors in vitro and in vivo; however, its clinical application is limited because it tends to easily undergo deamination metabolism. Therefore, we synthesized 4-N-carbobenzoxy-gemcitabine (Cbz-dFdC) as a lead prodrug and conducted a detailed pharmacokinetic, metabolic, and pharmacodynamic evaluation. After intragastric Cbz-dFdC administration, the Cmax of Cbz-dFdC and dFdC was 451.1 ± 106.7 and 1656.3 ± 431.5 ng/mL, respectively. The Tmax of Cbz-dFdC and dFdC was 2 and 4 h, respectively. After intragastric administration of Cbz-dFdC, this compound was mainly distributed in the intestine due to low carboxylesterase-1 (CES1) activity. Cbz-dFdC is activated by CES1 in both humans and rats. The enzyme kinetic curves were w</pubmed_abstract><journal>Molecules (Basel, Switzerland)</journal><pubmed_title>A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-N-Carbobenzoxy-gemcitabine (Cbz-dFdC).</pubmed_title><pmcid>PMC7248705</pmcid><funding_grant_id>81773826</funding_grant_id><pubmed_authors>Hao K</pubmed_authors><pubmed_authors>Sun Y</pubmed_authors><pubmed_authors>Wang J</pubmed_authors></additional><is_claimable>false</is_claimable><name>A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-N-Carbobenzoxy-gemcitabine (Cbz-dFdC).</name><description>Gemcitabine (dFdC) demonstrates significant effectiveness against solid tumors in vitro and in vivo; however, its clinical application is limited because it tends to easily undergo deamination metabolism. Therefore, we synthesized 4-N-carbobenzoxy-gemcitabine (Cbz-dFdC) as a lead prodrug and conducted a detailed pharmacokinetic, metabolic, and pharmacodynamic evaluation. After intragastric Cbz-dFdC administration, the Cmax of Cbz-dFdC and dFdC was 451.1 ± 106.7 and 1656.3 ± 431.5 ng/mL, respectively. The Tmax of Cbz-dFdC and dFdC was 2 and 4 h, respectively. After intragastric administration of Cbz-dFdC, this compound was mainly distributed in the intestine due to low carboxylesterase-1 (CES1) activity. Cbz-dFdC is activated by CES1 in both humans and rats. The enzyme kinetic curves were w</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 May</publication><modification>2025-04-05T14:02:14.127Z</modification><creation>2025-04-05T14:02:14.127Z</creation></dates><accession>S-EPMC7248705</accession><cross_references><pubmed>32397338</pubmed><doi>10.3390/molecules25092218</doi></cross_references></HashMap>